FCF YoY
-14.56%
OCF YoY
-17.56%
Capex YoY
-70.35%
FCF Conversion Δ
—
Free cash flow bridge for Alto Neuroscience (ANRO) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: −$7.99M
FCF bridge breakdown for Alto Neuroscience (ANRO) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | −$54.87M | — |
| Operating Cash Flow | −$9.31M | -116.5% |
| Capital Expenditure | $1.32M | +16.5% |
| Free Cash Outflow | −$62.86M | — |
- Prior Free Cash Flow−$54.87M
- Operating Cash Flow−$9.31M
- Capital Expenditure$1.32M
- Free Cash Outflow−$62.86M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Alto Neuroscience (ANRO) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement